Physician profile
H Mark Denson
NPI 1184789562
$3,366.12
in general payments reported to CMS, 2019-2025
27 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $148 · 2021: $566 · 2022: $623 · 2023: $524 · 2024: $525 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $748.93 | 2019-2025 | |
| Pfizer INC. | $430.07 | 2020-2025 | |
| Amgen INC. | $297.23 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.29 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $255.66 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $206.17 | 2019-2024 | Watchman, Watchman Flx |
| Merck Sharp & Dohme LLC | $196.33 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $152.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $111.99 | 2021-2025 | Farxiga |
| Heartflow, INC. | $88.38 | 2024-2025 | |
| Novo Nordisk INC | $84.92 | 2024-2025 | Wegovy |
| Abiomed | $59.86 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $56.32 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $51.93 | 2024-2025 | Amvuttra, Onpattro |
| Atricure, INC. | $48.18 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.56 | 2025 | |
| Philips North America LLC | $40.96 | 2024-2025 | (Ck4) Mcot, Mcot |
| Althera Pharmaceuticals LLC | $39.83 | 2021-2022 | |
| Cvrx, INC. | $32.47 | 2022 | |
| Esperion Therapeutics, INC. | $25.15 | 2021-2024 | Nexletol |
| Abbott Laboratories | $16.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.83 | 2021 | |
| G Medical Diagnostic Services, INC. | $14.11 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.79 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $13.62 | 2023 | Opsumit |
| Irhythm Technologies, INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Mark Denson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.